Department of Orthopaedic Surgery, Faculty of Medicine, Oita University, Oita, Japan.
Medicine (Baltimore). 2023 Sep 8;102(36):e34667. doi: 10.1097/MD.0000000000034667.
Although gelatin-thrombin matrix sealants have been used successfully in other surgery types, their effect on reducing blood loss during single-level transforaminal lumbar interbody fusion is unclear. We thus examined the efficacy of gelatin-thrombin matrix sealants for reducing blood loss during such surgery. We analyzed 102 patients who underwent single-level transforaminal lumbar interbody fusion for lumbar degenerative disease. We compared body mass index, surgical time, intraoperative blood loss, postoperative blood loss, true total blood loss, hidden blood loss, the proportion of blood transfusion, blood pressure pre- and post-surgery (systolic and diastolic), and pre-and post-surgery laboratory data (hemoglobin, hematocrit, platelets, prothrombin time, activated partial thromboplastin time, and D-dimer) between patients in whom gelatin-thrombin matrix sealants were (GTMS group) or were not (control group) used during surgery. One-week postoperative epidural hematoma size was measured using magnetic resonance imaging. The GTMS and control groups included 54 (24 males and 30 females) and 48 patients (19 males and 29 females). Intraoperative, true total, and hidden blood loss; epidural hematoma size; and hospitalization duration were significantly lower in the GTMS than in the control group. Intraoperative blood loss correlated with surgical time (R = 0.523, P = .001), body mass index (R = 0.221, P = .036), and the amount of gelatin-thrombin matrix sealant used (r = -0.313, P = .002). In multivariate linear regression analysis using intraoperative blood loss as the dependent variable, surgical time (standardization coefficient 0.516, P = .001) and amount of gelatin-thrombin matrix sealant used (standardization coefficient -0.220, P = .032) were independently related factors. In our study, the GTMS group had significantly less intraoperative true total and hidden blood loss than did the control group. Thus, use of gelatin-thrombin matrix sealants reduce perioperative blood loss in transforaminal lumbar interbody fusion.
虽然明胶-凝血酶基质密封剂已成功应用于其他手术类型,但它们在减少单节段经椎间孔腰椎体间融合术(TLIF)失血方面的效果尚不清楚。因此,我们研究了明胶-凝血酶基质密封剂在减少此类手术失血方面的疗效。我们分析了 102 例因腰椎退行性疾病行单节段 TLIF 的患者。我们比较了两组患者的体质量指数、手术时间、术中失血量、术后失血量、实际总失血量、隐匿性失血量、输血比例、手术前后血压(收缩压和舒张压)以及手术前后实验室数据(血红蛋白、红细胞压积、血小板、凝血酶原时间、活化部分凝血活酶时间和 D-二聚体)。术中使用明胶-凝血酶基质密封剂(GTMS 组)和未使用(对照组)的患者。术后 1 周使用磁共振成像测量硬膜外血肿大小。GTMS 组和对照组分别包括 54 例(24 例男性和 30 例女性)和 48 例(19 例男性和 29 例女性)患者。GTMS 组患者的术中、实际总失血量和隐匿性失血量、硬膜外血肿大小和住院时间均显著低于对照组。术中失血量与手术时间(R = 0.523,P =.001)、体质量指数(R = 0.221,P =.036)和明胶-凝血酶基质密封剂用量(r = -0.313,P =.002)相关。以术中失血量为因变量进行多元线性回归分析,手术时间(标准化系数 0.516,P =.001)和明胶-凝血酶基质密封剂用量(标准化系数 -0.220,P =.032)是独立的相关因素。在本研究中,GTMS 组患者术中实际总失血量和隐匿性失血量明显少于对照组。因此,使用明胶-凝血酶基质密封剂可减少 TLIF 围手术期失血。